Gilead Sciences Receives European Commission Approval for Sunlenca as HIV PrEP

Gilead Sciences today announced that the European Commission has approved Sunlenca (lenacapavir) as twice-yearly subcutaneous injection for HIV pre-exposure prophylaxis (PrEP) in adults and adolescents at risk for HIV in the European Union. The approval was based on results from the Phase 3 PURPOSE 1 and PURPOSE 2 trials, which demonstrated exceptional HIV prevention efficacy. This approval makes Sunlenca available as a long-acting PrEP option across all EU member states. Gilead is committed to ensuring broad access to Sunlenca in Europe and is working with national health authorities to facilitate reimbursement.